Ibrutinib covalently binds to the cysteine 481 (C481) residue of the BTK active site, irreversibly restraining the BCR signaling pathway, which contributes to reduced activation, migration, proliferation, and survival of CLL cells. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.